No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study.
Saved in:
| Title: | No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study. |
|---|---|
| Authors: | Prosperini L; Department of Neurosciences, S. Camillo-Forlanini Hospital, C.ne Gianicolense 87, 00152, Rome, Italy. luca.prosperini@gmail.com., Annovazzi P; MS Centre, S. Antonio Abate Hospital, Gallarate, VA, Italy., Boffa L; Department of Neurosciences, MS Center, Tor Vergata University, Rome, Italy., Buscarinu MC; Department of Neurosciences, Mental Health and Sensory Organs, Sapienza University, S. Andrea Hospital, Rome, Italy., Gallo A; Department of Medical, Surgical, Neurological, Metabolic and Aging Sciences, University of Campania 'Luigi Vanvitelli', Naples, Italy., Matta M; Regional MS Centre, S. Luigi Gonzaga Hospital, Orbassano, TO, Italy., Moiola L; Department of Neurology, Institute of Experimental Neurology, Division of Neuroscience, S. Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy., Musu L; MS Center, Binaghi Hospital, ASSL Cagliari, ATS regione Sardegna, Cagliari, Italy., Perini P; Department of Neurosciences, MS Centre, University Hospital, Padua, Italy., Avolio C; Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy., Barcella V; MS Center, ASST Papa Giovanni XXIII, Bergamo, MI, Italy., Bianco A; Fondazione Policlinico A. Gemelli, IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy., Farina D; Department of Neuroscience and Imaging, University 'G. d'Annunzio', Chieti, Italy., Ferraro E; Neurology Unit, S. Filippo Neri Hospital, Rome, Italy., Pontecorvo S; Department of Neurology and Psychiatry, Sapienza University, Rome, Italy., Granella F; Department of Medicine and Surgery, University of Parma, Parma, Italy., Grimaldi LME; U.O.C. Neurologia, Fondazione Istituto 'G.Giglio, Cefalù, PA, Italy., Laroni A; Department of Neurology, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI) and Center of Excellence for Biomedical Research (CEBR), University of Genoa, Genoa, Italy.; Departement of Neurosciences, IRCCS Osp. Policlinico S. Martino, Genoa, Italy., Lus G; Department of Medical, Surgical, Neurological, Metabolic and Aging Sciences, University of Campania 'Luigi Vanvitelli', Naples, Italy., Patti F; Department of Medical and Surgical Sciences and Advanced Technologies, Neuroscience Section, University of Catania, Catania, Italy., Pucci E; UOC Neurologia Ospedale 'A. Murri', ASUR Marche - AV4, Fermo, Italy., Pasca M; Department of Neurofarba, University of Florence, Florence, Italy., Sarchielli P; Neurology Unit, Osp.e Santa Maria della Misericordia, University of Perugia, Perugia, Italy. |
| Corporate Authors: | Italian Alemtuzumab Study Group |
| Source: | Journal of neurology [J Neurol] 2018 Dec; Vol. 265 (12), pp. 2851-2860. Date of Electronic Publication: 2018 Sep 26. |
| Publication Type: | Journal Article; Multicenter Study; Observational Study |
| Journal Info: | Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 0423161 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-1459 (Electronic) Linking ISSN: 03405354 NLM ISO Abbreviation: J Neurol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1432-1459 |
|---|---|
| DOI: | 10.1007/s00415-018-9070-x |
